Esposito Angela, Criscitiello Carmen, Trapani Dario, Curigliano Giuseppe
Division of Experimental Cancer Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141+, Milan, Italy.
Curr Oncol Rep. 2017 Jan;19(1):1. doi: 10.1007/s11912-017-0564-y.
Therapeutic advances in the treatment of lung cancer are in part due to a more complete understanding of its genomic portrait. The serial monitoring of tumor genotypes, which are instable and prone to changes under selective pressure, is becoming increasingly needed. Although tumor biopsies remain the reference standard for the diagnosis and genotyping of lung cancer, they are invasive and not always feasible. The "liquid biopsies" have the potential to overcome many of these hurdles, allowing a rapid and accurate identification of de novo and resistant genetic alterations and a real-time monitoring of treatment responses. In this review, we provide insights into new liquid diagnostic platforms and discuss the role of circulating tumor cells and circulating tumor DNA in the diagnosis and identification of resistance mutations in lung cancer.
肺癌治疗的进展部分归功于对其基因组特征有了更全面的了解。由于肿瘤基因型不稳定且在选择性压力下容易发生变化，因此对肿瘤基因型进行连续监测的需求日益增加。尽管肿瘤活检仍是肺癌诊断和基因分型的参考标准，但它们具有侵入性，且并非总是可行。“液体活检”有潜力克服其中许多障碍，能够快速、准确地识别新出现的和耐药的基因改变，并实时监测治疗反应。在本综述中，我们深入探讨了新的液体诊断平台，并讨论了循环肿瘤细胞和循环肿瘤DNA在肺癌诊断及耐药突变识别中的作用。
